Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Colorcon
Dow
Johnson and Johnson
McKesson

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR GEMTUZUMAB OZOGAMICIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Gemtuzumab Ozogamicin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003131 ↗ CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse Completed Pfizer Phase 2 1997-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid leukemia in first relapse.
NCT00003673 ↗ CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse Completed Pfizer Phase 2 1998-03-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute myeloid leukemia that has recurred for the first time following at least 3 months of complete remission.
NCT00005962 ↗ Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 2 2000-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Combining more than one drug or combining monoclonal antibody with chemotherapy may kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia. PURPOSE: Randomized phase II trial to compare the effectiveness of three treatment regimens in treating patients who have relapsed or refractory acute myelogenous leukemia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gemtuzumab Ozogamicin

Condition Name

Condition Name for Gemtuzumab Ozogamicin
Intervention Trials
Acute Myeloid Leukemia 33
Leukemia 24
Myelodysplastic Syndrome 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gemtuzumab Ozogamicin
Intervention Trials
Leukemia 83
Leukemia, Myeloid, Acute 80
Leukemia, Myeloid 76
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gemtuzumab Ozogamicin

Trials by Country

Trials by Country for Gemtuzumab Ozogamicin
Location Trials
United States 489
Canada 33
Germany 12
United Kingdom 11
Australia 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gemtuzumab Ozogamicin
Location Trials
Texas 23
New York 23
California 21
Washington 19
Michigan 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gemtuzumab Ozogamicin

Clinical Trial Phase

Clinical Trial Phase for Gemtuzumab Ozogamicin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 16
Phase 2/Phase 3 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gemtuzumab Ozogamicin
Clinical Trial Phase Trials
Completed 46
Recruiting 24
Terminated 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gemtuzumab Ozogamicin

Sponsor Name

Sponsor Name for Gemtuzumab Ozogamicin
Sponsor Trials
National Cancer Institute (NCI) 31
Pfizer 16
M.D. Anderson Cancer Center 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gemtuzumab Ozogamicin
Sponsor Trials
Other 98
Industry 35
NIH 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Medtronic
Harvard Business School
Moodys
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.